Skip to main content
Equibles
MXCT logo

MXCT · Maxcyte, Inc. · Metrics

Track MXCT — free

Use MXCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MXCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.47 +0.04 (+2.80%)
Rebalance outlook locked
Market Cap
$147.58M
Shares
103.21M
Volume · Oct 21 1.42M Avg daily vol (3M) 849.89K

MXCT metrics

88 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.47
Market cap
$147.58M

Price action

20 metrics
Price change (1W)
+48.3%
Price change (30D)
+17.2%
Price change (3M)
+16.3%
Price change (6M)
+64.4%
Price change (YTD)
-7.7%
Price change (1Y)
-18.3%
Trailing year
Price change (5Y)
-86.8%
52-week high
$1.76
52-week low
$0.68
Change from 52-week high
-18.8%
Change from 52-week low
+111.5%
Annualized volatility
71.4%
Annualized volatility (3M)
82.2%
Beta
1.4
RSI (14D)
71.3
Price vs SMA 50
+17.1%
Price vs SMA 200
+35.2%
Avg volume (3M)
836,572
Relative volume
1.7
Average dollar volume
$1.03M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
103.21M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.9×
reciprocal yield 109.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
4.3×
reciprocal yield 23.1%
P / book
0.8
reciprocal yield 118.3%
FCF yield
-17.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-26.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
3.5×
reciprocal yield 28.9%
EV / revenue historical average (5Y)
4.5×
reciprocal yield 22.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-10
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
79.2%
Operating margin
-134.6%
Trailing 12 months
Net margin
-114.8%
Gross profit (TTM)
$24.60M
Operating profit (TTM)
−$41.79M
Net income (TTM)
−$35.64M
Trailing 12 months
Diluted EPS (TTM)
$-0.32
FCF margin
-76.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.29
Gross profit per diluted share (TTM)
$0.23
Operating profit per diluted share (TTM)
$-0.39
EBITDA per diluted share (TTM)
$-0.35
Net income per diluted share (TTM)
$-0.33
Operating cash flow per diluted share (TTM)
$-0.22
Free cash flow per diluted share (TTM)
$-0.22
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.16
Stock compensation per diluted share (TTM)
$0.05
Book value per share
$1.61

Growth

11 metrics
Revenue growth YoY
-14.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$31.05M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.4%
Year over year · more shares
Revenue CAGR (3Y)
-9.3%
Revenue CAGR (5Y)
+4.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-22.4%
Return on assets
-19.3%
Debt / equity
0.0
Current ratio
12.3
EBITDA (TTM)
−$37.63M
Free cash flow (TTM)
−$23.64M
Quick ratio
11.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$105.69M
Latest balance sheet
Cash & equivalents
$15.04M
Total assets
$184.67M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$22.98M
Capital expenditures (TTM)
$665,000
R&D (TTM)
$16.76M
SG&A (TTM)
—
Stock compensation (TTM)
$4.96M
R&D / revenue
54.0%
Stock compensation / revenue
16.0%

Ownership (13F)

9 metrics
13F filers
122
13F filer change QoQ
-9
Institutional ownership
61.4%
Conviction holders (share of 13F filers)
0.8%
Crowding (high-turnover and private-fund holders)
27.0%
Private-fund adviser ownership
24.6%
Active holders' share change QoQ
+19.2%
Holder tenure
9.1
Price vs estimated holder cost
-64.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
7.5%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 3.1 days to cover
Days to cover
3.1d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1287098 CUSIP 57777K106 13F (30d) 11 filings 11 filers Visit website Investor relations